65373-52-6

Usage

Uses

Used in Pharmaceutical Industry:
Oxazole-2-carbaldehyde is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to form a wide range of biologically active compounds, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, Oxazole-2-carbaldehyde serves as a building block for the creation of agrochemicals, including pesticides and herbicides, due to its reactivity and potential to form compounds with pesticidal properties.
Used in Dye Production:
Oxazole-2-carbaldehyde is utilized as a precursor in the production of dyes, where its chemical structure allows for the creation of dyes with specific color characteristics and properties.
Used in Perfumery:
Oxazole-2-carbaldehyde is employed as a raw material in the perfume industry, where its unique odor profile can be used to create distinctive fragrances.
Used in Flavor Industry:
Oxazole-2-carbaldehyde is used in the flavor industry to develop flavoring agents, capitalizing on its strong and pungent odor to enhance or create specific taste profiles in food products.

InChI:InChI=1/C4H3NO2/c6-3-4-5-1-2-7-4/h1-3H

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 288-42-6 oxazol 
• 4394-85-8 4-morpholinecarboxaldehyde 
• 154093-80-8 2-oxazolyl lithium 

Downstream Products

• 130551-92-7 (1,3-oxazol-2-yl)methanol 
• 916220-09-2 oxazol-2-yl(4-(tetrahydro-2H-pyran-2-yloxy)phenyl)methanol 
• 1398718-70-1 C₁₅H₁₈BrN₃O 
• 1446183-03-4 5-amino-2-(oxazol-2-yl)-4-phenylthiazole 
• 929713-54-2 oxazol-5-yl(4-(tetrahydro-2H-pyran-2-yloxy)phenyl)methanol 
• 1059544-51-2 (E)-2-styryloxazole 
• 1202248-72-3 (Z)-2-styryloxazole 
• 1219004-99-5 (4S)-3-[(2S,3S)-2-(biphenyl-4-ylmethoxy)-3-hydroxy-2-methyl-3-(1,3-oxazol-2-yl)propanoyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one 
• 23419-15-0 C₁₀H₇N₃O 
• 866640-97-3 2-[2,6-dimethyl-4-[[(oxazol-2-ylmethyl)amino]methyl]phenoxy]-2-methylpropanoic acid ethyl ester 

Relevant academic research and scientific papers

Effect of the positional isomerism on the photoreactivity of styryloxazoles

This paper describes the results obtained in the study of the photobehaviour of heteroanalogs of stilbene bearing an oxazole ring. The competitive relaxation processes (fluorescence, isomerization and cyclization) of the excited states of n-styryloxazoles (n = 2 and 4) were investigated and compared with the behaviour previously reported for n = 5. After preparation of the unknown compound with n = 4 and of its positional isomer with n = 2 (the latter with a new method of synthesis), their photobehaviour was firstly investigated in preparative conditions by NMR analysis to measure the chemical yields of their photoproducts. The study was then continued in mild irradiation conditions to measure the quantum yields of the competitive photoreactions in the primary irradiation steps. The effects of the position of the styryl group at the oxazole ring, the relative abundance of the various conformers and the possible formation of intramolecular H-bonds on the deactivation pathways are described. Quantum-mechanical Hyperchem calculations proved to be very useful to describe the conformational equilibria and the role of conformers on photoreactivity while more refined DFT calculations on the Z isomers allowed to explain the structure dependent competition between their isomerization/cyclization processes. The effect of the replacement of the phenyl ring with a second heteroaromatic group of electron donor character was investigated for the 5-(2-(furan-2-yl) ethenyl) oxazole.

HETEROCYCLIC GTP CYCLOHYDROLASE 1 INHIBITORS FOR THE TREATMENT OF PAIN

The present invention relates to the field of small molecule heterocyclic inhibitors of GTP cyclohydrolase (GCH-I), or a tautomer, prodrug, or pharmaceutically acceptable salt thereof. The invention also features pharmaceutical compositions of the compounds and the medical use of these compounds for the treatment or prevention of pain (e.g., inflammatory pain, nociceptive pain, functional pain, or neuropathic pain).

INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS

The present invention relates to novel compounds, in particular, novel indazole that may be used as melanin concentrating hormone receptor ligands, methods of preparing such compounds, compositions containing such compounds, and methods of using such compounds to treat MCH related disorders.

PHENOXYACETIC ACID DERIVATIVES AND DRUGS USING THE SAME

It is intended to provide a novel compound having an excellent agonism to PPARs α/γ and desirable properties as a drug. An agonist to peroxisome proliferator-activated receptors α/γ which is represented by the general formula (I) (wherein Q represents an optionally substituted benzene ring or pyridine ring; R1 and R2 represent each an optionally substituted phenyl group or a 5- to 6-membered aromatic heterocycle group; X, Y and Z independently represent each C, O, S or N; R3 to R9 represent each a hydrogen atom, a lower alkyl group, etc.; and n is an integer of from 0 to 3.

4- (IH-INDAZOL-S-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER

A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blood

PHENOXYACETIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME

Novel compounds having excellent PPAR α/γ agonist effects and having desirable properties for medicaments are provided. Peroxisome proliferator-activated receptor α/γ agonists of the general formula (I): (wherein Q is an optionally-substituted benzene or

NOVEL ANDROGENS

The compounds of the subject invention have a structure according to formula I: wherein X is S or SO2; R1 is (1C-6C)alkyl, (3C-6C)alkenyl, or (3C-6C)alkynyl, each optionally subst ituted with (3C-6C)cycloalkyl, OH, OC(O)(1C-4C)alkyl, (1C- 4C)alkoxy, halogen, cyano, formyl, C(O)(1C-4C)alkyl, CO2H, CO2(1C- 4C)alkyl, C(O)NR5R6, S(O)(1C-4C)alkyl or S(O)2(1C-4C)alkyl; R2 is hydrogen, (1C-4C)alkyl or C(O)(1C-4C)alkyl; R3 is a phenyl group optionally substituted with (1C-4C)alkyl, (1C-4C)fluoroalkyl, (1C-4C)alkoxy, (1C-4C)fluoroalkoxy, halogen, cyano or nitro; or R3 is a 5- or 6-membered aromatic heterocyclic ring structure optionally substituted with (1C-4C)alkyl, (1C-4C)fluoroalkyl, (1C-4C)alkoxy, halogen or cyano; R4 is a phenyl group or an aromatic 6-membered heterocycle, substituted at the ortho position with 1-hydroxy(1C-4C)alkyl, (1C-4C)alkoxy, C(O)(1C- 4C)alkyl, CO2(1C-4C)alkyl, C(O)NH2, cyano, nitro, or CH=NOR7, and optionally further substituted with (1C-2C)alkyl, (1C-2C)fluoroalkyl or halogen; R5 is 2-pyridyl optionally substituted with (1C-2C)alkyl, (1C- 2C)fluoroalkyl or halogen; or R5 and R6 are independently hydrogen or (1C-4C)alkyl; R7 is hydrogen or C(O)(1C-4C)alkyl; R8 , R9 , R10 are independently hydrogen, (1C-2C)alkyl, fluoro or chloro; or a salt or hydrate form thereof.

1-cyclopropyl-4-pyridyl-quinolinones

Compounds of formula STR1 wherein R1 is hydrogen, lower-alkyl, or trifluoromethyl; R2 is lower-alkyl, trifluoromethyl or CH2 Z where Z is hydroxy, chloro, lower-alkylamino or dilower-alkylamino; R3 and R4 are each individually hydrogen or fluoro; and Ar is phenyl, an aromatic 5- or 6-membered heterocycle or any of these substituted at one or more positions with lower-alkyl, fluoro, chloro, hydroxy, amino, lower-alkylamino, dilower-alkylamino, carboxy, sulfonamido, lower alkylsulfonamido, methylenedioxy, trifluoroacetamido, lower-alkanoylamino, or carbamoyl; and their pharmaceutically acceptable acid addition salts are useful as anticancer agents.